Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

PARP inhibitor

- PMLiVE

AZ gets green light for Bydureon pen in US

FDA approval comes after year-long delay

- PMLiVE

AZ gets limited approval for metreleptin in US

First FDA-backed treatment for rare disease lipodystrophy

- PMLiVE

Teva’s Symbicort generic backed for EU approval

AstraZeneca braces for competition to COPD drug

- PMLiVE

FDA to review safety of AZ’s saxagliptin

Diabetes drug linked to heart failure

- PMLiVE

Soriot says pipeline will speed recovery at AZ

Diabetes franchise among new products expected to return company to growth

- PMLiVE

AZ shutters R&D unit in India

Local reports says pharma company will transfer operations to UK and outsourcing partners

- PMLiVE

AZ gets green light in EU for Xigduo diabetes combination

Wins approval for first line extension of Forxiga

- PMLiVE

AZ’s Soriot upbeat on firm’s prospects

Says pharma company can return to growth by 2017

- PMLiVE

2013 – biotech boomed

The $10bn-plus strategic acquisition returned and pharma companies sought to replenish their pipelines

- PMLiVE

FDA clears BMS/AZ’s dapagliflozin at second attempt

Diabetes drug approved as companies look to end alliance

AZ agrees cancer alliance with Immunocore

Medimmune subsidiary will work with biotech on encouraging patient's immune system to tackle tumours

- PMLiVE

AstraZeneca expands personalised drug partnership with Horizon

Companies will research drug targets for targeted cancer treatments

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links